Skip to main content
Donate
FAST Logo

Welcome to the Foundation for Angelman Syndrome Therapeutics

We have one goal: to cure Angelman syndrome.

Announcement ideogram illustration

Registration opens Aug 1st!

Save the Date: 18th FAST Global Science Summit & Gala on Nov 7-8, 2025 – click to learn more!

Allyson Berent speaking at the FAST Global Science Summit & Gala
Families category image

For Families & Caregivers Learn More

Research category image

For Researchers Learn More

Families category image

For Industry Learn More

Donors category image

For Donors Learn More

Not sure where to go? Start Here

Cover photos for our What is Angelman Syndrome call to action section

What is
Angelman Syndrome?

Angelman syndrome (AS) is a rare genetic condition that affects the nervous system, leading to challenges with movement, balance, and communication. It is caused by changes to chromosome 15, which impact brain function.

Learn More

FAST Angelman Syndrome News

Investing in the Future of Angelman Syndrome Research: FAST Partners with ASGCT to Support Early-Career...

First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome

FAST Announces Funding For First Innovative Seed Grant

Leading Neurology and Rare Disease Expert Dr. Nick France Joins FAST Board

CAN SPOTLIGHT: Skating Angels Charity Ice Hockey Tournament

CAN Spotlight: Kettlebells for Kayleigh Fundraiser in Germany

More Than a Seat at the Table: FAST’s Role in Shaping the Future of Angelman Syndrome at ASGCT 2025

MavriX Bio Announces FDA Clearance of IND Application to Initiate First-in-Human Study of Gene Therapy ...

Expanding the Pre-Clinical Research Landscape for Angelman Syndrome

FAST Speaks at the 2025 MENA Congress for Rare Diseases

Oak Hill Bio to continue the development of rugonersen, an investigational ASO previously owned by Roch...

FAST-funded researcher highlights the involvement of UBE3A in different neurodegenerative diseases

CAN Spotlight: Bike 4 Briar Starts May 27th!

Progress for Angelman Syndrome Relies on a Strong NIH and FDA

IONIS REVEAL Phase 3 Clinical Trial Update

Exciting Announcement: Launch of Our New Electronic Journal

Community Update: New Insights into Health and Prevention in Angelman Syndrome

The Economic Burden of Caring for Individuals with Angelman Syndrome

CAN Spotlight: Matthew Gocker continues to support AS Family in Wisconsin!

FAST Poland Organized the 1st Polish National Angelman Syndrome Conference

Investing in the Future of Angelman Syndrome Research: FAST Partners with ASGCT to Support Early-Career...

First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome

FAST Announces Funding For First Innovative Seed Grant

Leading Neurology and Rare Disease Expert Dr. Nick France Joins FAST Board

CAN SPOTLIGHT: Skating Angels Charity Ice Hockey Tournament

CAN Spotlight: Kettlebells for Kayleigh Fundraiser in Germany

More Than a Seat at the Table: FAST’s Role in Shaping the Future of Angelman Syndrome at ASGCT 2025

MavriX Bio Announces FDA Clearance of IND Application to Initiate First-in-Human Study of Gene Therapy ...

Expanding the Pre-Clinical Research Landscape for Angelman Syndrome

FAST Speaks at the 2025 MENA Congress for Rare Diseases

Oak Hill Bio to continue the development of rugonersen, an investigational ASO previously owned by Roch...

FAST-funded researcher highlights the involvement of UBE3A in different neurodegenerative diseases

CAN Spotlight: Bike 4 Briar Starts May 27th!

Progress for Angelman Syndrome Relies on a Strong NIH and FDA

IONIS REVEAL Phase 3 Clinical Trial Update

Exciting Announcement: Launch of Our New Electronic Journal

Community Update: New Insights into Health and Prevention in Angelman Syndrome

The Economic Burden of Caring for Individuals with Angelman Syndrome

CAN Spotlight: Matthew Gocker continues to support AS Family in Wisconsin!

FAST Poland Organized the 1st Polish National Angelman Syndrome Conference

Disclaimer

This website contains information for a broad audience and may include information on current and upcoming programs that are not yet approved or accessible The information provided is for general informational purposes only and is not intended as medical advice, diagnosis, or treatment. While FAST strives to provide accurate and up-to-date information, the content on this site may not always reflect the most current research or clinical guidelines. The inclusion of clinical trial information, treatments or specific healthcare providers does not imply endorsement, recommendation or guarantee of safety, efficacy, or availability. Reliance on any information provided by this website is solely at your own risk. FAST disclaims any liability for any errors or omissions in the information provided or for any decisions made based on this information. For personalized medical advice or specific health concerns including participation in any clinical trial, please consult a qualified healthcare professional.